All patients being treated with bupropion for smoking cessation treatment should be observed for neuropsychiatric symptoms including changes in behavior, hostility
1 Its unique mechanism of
change in sense of taste
Spier evaluated the use of adding bupropion to patients with MDD in a private practice clinic already on venlafaxine or an SSRI in an open-label trial assessing symptom relief and management of drug-induced side effects in monotherapy nonresponders (n = 15) and responders (n = 10) with side effects
4% of patients undergoing bupropion therapy at dosages up to 450 mg daily
This medication should be started a week before your quit date because it takes about a week for it to start working
per dose 150 mg), minimum 8 hours between doses; period of treatment 7–9 weeks, start treatment 1–2 weeks before target stop date
1 General Instructions for Use - To minimize the risk of seizure, increase the dose gradually [see Warnings and
Approval Letter(s) (PDF) Printed Labeling (PDF) Medical Review(s) (PDF) Chemistry Review(s) (PDF) Clinical Pharmacology Biopharmaceutics Review U
See also Warning section
Wellbutrin XL package insert / prescribing information for healthcare professionals
153 WELLBUTRIN XL 300 mg once daily was shown to have bioavailability that was similar to that
WELLBUTRIN XL ® (bupropion hydrochloride) Extended-Release Tablets In accordance with 21 CFR 208
WELLBUTRIN SR® (bupropion hydrochloride) Sustained-Release Tablets 4 significant difference in C max, half-life, t max, AUC, or clearance of bupropion or its active metabolites between smokers and nonsmokers
Bupropion comes as immediate-release (IR), sustained-release (SR), and extended-release (ER or XL) tablets
The median dosage of bupropion SR in the 8 women was 262